Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Human leukocyte antigen class II expression is a good prognostic factor in adult T-cell leukemia/lymphoma.

Takeuchi M, Miyoshi H, Asano N, Yoshida N, Yamada K, Yanagida E, Moritsubo M, Nakata M, Umeno T, Suzuki T, Komaki S, Muta H, Furuta T, Seto M, Ohshima K.

Haematologica. 2019 Aug;104(8):1626-1632. doi: 10.3324/haematol.2018.205567. Epub 2019 Jan 10.

2.

The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.

Imai D, Yoshizumi T, Okano S, Uchiyama H, Ikegami T, Harimoto N, Itoh S, Soejima Y, Aishima S, Oda Y, Maehara Y.

Cancer Med. 2017 Jul;6(7):1614-1626. doi: 10.1002/cam4.1087. Epub 2017 Jun 10.

3.

Expression pattern of immunosurveillance-related antigen in adult T cell leukaemia/lymphoma.

Asano N, Miyoshi H, Kato T, Shimono J, Yoshida N, Kurita D, Sasaki Y, Kawamoto K, Ohshima K, Seto M.

Histopathology. 2018 May;72(6):945-954. doi: 10.1111/his.13461. Epub 2018 Feb 21.

PMID:
29297942
4.

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project.

Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM, Weisenberger DD, Chan WC, Muller-Hermelink HK, Jaffe ES, Gascoyne RD, Campo E, Fuchs DA, Spier CM, Fisher RI, Delabie J, Rosenwald A, Staudt LM, Grogan TM.

Blood. 2004 Jun 1;103(11):4251-8. Epub 2004 Feb 19.

PMID:
14976040
5.

Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy.

Umemoto Y, Okano S, Matsumoto Y, Nakagawara H, Matono R, Yoshiya S, Yamashita Y, Yoshizumi T, Ikegami T, Soejima Y, Harada M, Aishima S, Oda Y, Shirabe K, Maehara Y.

J Gastroenterol. 2015 Jan;50(1):65-75. doi: 10.1007/s00535-014-0933-3. Epub 2014 Feb 8.

PMID:
24509608
6.

Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung.

Han YB, Kwon HJ, Park SY, Kim ES, Kim H, Chung JH.

J Pathol Transl Med. 2019 Mar;53(2):86-93. doi: 10.4132/jptm.2018.12.26. Epub 2019 Jan 14.

7.

HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma.

Diepstra A, van Imhoff GW, Karim-Kos HE, van den Berg A, te Meerman GJ, Niens M, Nolte IM, Bastiaannet E, Schaapveld M, Vellenga E, Poppema S.

J Clin Oncol. 2007 Jul 20;25(21):3101-8. Epub 2007 May 29.

PMID:
17536082
8.

HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma.

Jesionek-Kupnicka D, Bojo M, Prochorec-Sobieszek M, Szumera-Ciećkiewicz A, Jabłońska J, Kalinka-Warzocha E, Kordek R, Młynarski W, Robak T, Warzocha K, Lech-Maranda E.

Arch Immunol Ther Exp (Warsz). 2016 Jun;64(3):225-40. doi: 10.1007/s00005-015-0372-8. Epub 2015 Dec 14.

PMID:
26667793
9.

Prognostic significance of HLA class I and II expression in patients with diffuse large B cell lymphoma treated with standard chemoimmunotherapy.

Tada K, Maeshima AM, Hiraoka N, Yamauchi N, Maruyama D, Kim SW, Watanabe T, Katayama N, Heike Y, Tobinai K, Kobayashi Y.

Cancer Immunol Immunother. 2016 Oct;65(10):1213-22. doi: 10.1007/s00262-016-1883-9. Epub 2016 Aug 13.

PMID:
27522583
10.

Downregulated expression of human leukocyte antigen class I heavy chain is associated with poor prognosis in non-small-cell lung cancer.

Ichinokawa K, Nakanishi Y, Hida Y, Tsuchikawa T, Kato T, Itoh T, Kaji M, Kaga K, Hirano S.

Oncol Lett. 2019 Jul;18(1):117-126. doi: 10.3892/ol.2019.10293. Epub 2019 Apr 30.

11.

PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma.

Miyoshi H, Kiyasu J, Kato T, Yoshida N, Shimono J, Yokoyama S, Taniguchi H, Sasaki Y, Kurita D, Kawamoto K, Kato K, Imaizumi Y, Seto M, Ohshima K.

Blood. 2016 Sep 8;128(10):1374-81. doi: 10.1182/blood-2016-02-698936. Epub 2016 Jul 14.

PMID:
27418641
12.
13.

Clinical implications of human leukocyte antigen class I expression in endometrial cancer.

Yakabe K, Murakami A, Nishimoto Y, Kajimura T, Sueoka K, Sugino N.

Mol Clin Oncol. 2015 Nov;3(6):1285-1290. Epub 2015 Sep 3.

14.

The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.

Talebian Yazdi M, van Riet S, van Schadewijk A, Fiocco M, van Hall T, Taube C, Hiemstra PS, van der Burg SH.

Oncotarget. 2016 Jan 19;7(3):3477-88. doi: 10.18632/oncotarget.6506.

15.

Prognostic value of HLA class I expression in patients with colorectal cancer.

Iwayama Y, Tsuruma T, Mizuguchi T, Furuhata T, Toyota N, Matsumura M, Torigoe T, Sato N, Hirata K.

World J Surg Oncol. 2015 Feb 12;13:36. doi: 10.1186/s12957-015-0456-2.

16.

The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration.

Perea F, Bernal M, Sánchez-Palencia A, Carretero J, Torres C, Bayarri C, Gómez-Morales M, Garrido F, Ruiz-Cabello F.

Int J Cancer. 2017 Feb 15;140(4):888-899. doi: 10.1002/ijc.30489. Epub 2016 Nov 7.

17.

The prognostic impact of human leukocyte antigen (HLA) class I antigen abnormalities in salivary gland cancer. A clinicopathological study of 288 cases.

Müller M, Agaimy A, Zenk J, Ettl T, Iro H, Hartmann A, Seliger B, Schwarz S.

Histopathology. 2013 May;62(6):847-59. doi: 10.1111/his.12086.

PMID:
23611358
18.

Prognostic impact of the tumor immune microenvironment in synovial sarcoma.

Oike N, Kawashima H, Ogose A, Hotta T, Hatano H, Ariizumi T, Sasaki T, Yamagishi T, Umezu H, Endo N.

Cancer Sci. 2018 Oct;109(10):3043-3054. doi: 10.1111/cas.13769. Epub 2018 Sep 16.

19.

The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.

Sugita Y, Furuta T, Ohshima K, Komaki S, Miyoshi J, Morioka M, Abe H, Nozawa T, Fujii Y, Takahashi H, Kakita A.

Neuropathology. 2018 Apr;38(2):125-134. doi: 10.1111/neup.12435. Epub 2017 Oct 24.

PMID:
29067721
20.

HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?

Nijland M, Veenstra RN, Visser L, Xu C, Kushekhar K, van Imhoff GW, Kluin PM, van den Berg A, Diepstra A.

Oncoimmunology. 2017 Mar 3;6(4):e1295202. doi: 10.1080/2162402X.2017.1295202. eCollection 2017.

Supplemental Content

Support Center